Kainos Medicine

Kainos Medicine, Inc., headquartered in South Korea, is a clinical-stage drug development company specializing in the research and development of innovative drugs for brain diseases, cancer, and infectious diseases, led by researchers with many years of experience and a successful track record. The company’s product pipeline includes KM-819, which is currently in Phase I clinical trials for the treatment of Parkinson's disease, and KM023, a novel non-nucleoside reverse transcriptase inhibitor, which is in Phase II clinical trials for the treatment of HIV/AIDS.